Journal article

Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules

Zheng Quan Toh, Jennie Kosasih, Fiona M Russell, Rita Reyburn, James Fong, Evelyn Tuivaga, Felisita T Ratu, Cattram D Nguyen, Silivia Matanitobua, Lien Anh Ha Do, Trevelyan Menheniott, Ian H Frazer, Suzanne M Garland, Edward Kim Mulholland, Paul V Licciardi

Vaccines | MDPI | Published : 2019

Abstract

The duration of cross-neutralising antibody responses (cross-NAb) following HPV immunisation is unknown. We compared cross-NAb responses in cohort of girls who were either unimmunised or had received immunisation with one, two or three doses of 4vHPV (Gardasil®,Merck Inc.) six years earlier, before and one month after a booster dose of 2vHPV (Cervarix®, GSK). NAb to potentially cross-reactive HPV genotypes 31, 33, 45, 52 and 58 were measured using a HPV pseudovirion-based neutralisation assay. Girls who had previously received at least one dose of 4vHPV had significantly higher NAb titres for HPV31 when compared with unimmunised girls, whereas no difference in NAb titre was observed for four..

View full abstract

Grants

Funding Acknowledgements

The fieldwork for this study was supported by the Department of Foreign Affairs and Trade of the Australian government and the Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by ABT Associates on behalf of the Australian government. This work was also supported in part by the Victorian Government's Operational Infrastructure Support Program, as well as Murdoch Children's Research Institute internal theme funding. F.M.R., T.M. and P.V.L. are recipients of National Health and Medical Research Council Fellowships.